|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WDR74 |
Gene summary for WDR74 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WDR74 | Gene ID | 54663 |
| Gene name | WD repeat domain 74 | |
| Gene Alias | Nsa1 | |
| Cytomap | 11q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0001701 | UniProtAcc | Q6RFH5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54663 | WDR74 | LZE4T | Human | Esophagus | ESCC | 2.93e-14 | 3.07e-01 | 0.0811 |
| 54663 | WDR74 | LZE5T | Human | Esophagus | ESCC | 4.06e-03 | 2.08e-01 | 0.0514 |
| 54663 | WDR74 | LZE7T | Human | Esophagus | ESCC | 3.28e-10 | 5.54e-01 | 0.0667 |
| 54663 | WDR74 | LZE8T | Human | Esophagus | ESCC | 7.09e-09 | 1.79e-01 | 0.067 |
| 54663 | WDR74 | LZE21D1 | Human | Esophagus | HGIN | 1.73e-04 | 5.70e-01 | 0.0632 |
| 54663 | WDR74 | LZE22T | Human | Esophagus | ESCC | 9.54e-03 | 5.30e-01 | 0.068 |
| 54663 | WDR74 | LZE24T | Human | Esophagus | ESCC | 8.07e-26 | 7.89e-01 | 0.0596 |
| 54663 | WDR74 | LZE21T | Human | Esophagus | ESCC | 2.00e-05 | 3.02e-01 | 0.0655 |
| 54663 | WDR74 | LZE6T | Human | Esophagus | ESCC | 3.16e-03 | 3.09e-01 | 0.0845 |
| 54663 | WDR74 | P1T-E | Human | Esophagus | ESCC | 1.40e-11 | 7.25e-01 | 0.0875 |
| 54663 | WDR74 | P2T-E | Human | Esophagus | ESCC | 2.98e-29 | 5.50e-01 | 0.1177 |
| 54663 | WDR74 | P4T-E | Human | Esophagus | ESCC | 9.81e-41 | 1.11e+00 | 0.1323 |
| 54663 | WDR74 | P5T-E | Human | Esophagus | ESCC | 3.07e-32 | 9.29e-01 | 0.1327 |
| 54663 | WDR74 | P8T-E | Human | Esophagus | ESCC | 8.18e-34 | 6.57e-01 | 0.0889 |
| 54663 | WDR74 | P9T-E | Human | Esophagus | ESCC | 3.86e-26 | 6.31e-01 | 0.1131 |
| 54663 | WDR74 | P10T-E | Human | Esophagus | ESCC | 8.35e-20 | 3.93e-01 | 0.116 |
| 54663 | WDR74 | P11T-E | Human | Esophagus | ESCC | 1.03e-10 | 6.76e-01 | 0.1426 |
| 54663 | WDR74 | P12T-E | Human | Esophagus | ESCC | 3.90e-28 | 7.29e-01 | 0.1122 |
| 54663 | WDR74 | P15T-E | Human | Esophagus | ESCC | 9.11e-21 | 3.88e-01 | 0.1149 |
| 54663 | WDR74 | P16T-E | Human | Esophagus | ESCC | 7.64e-19 | 5.51e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002261327 | Esophagus | HGIN | ribonucleoprotein complex biogenesis | 158/2587 | 463/18723 | 2.61e-29 | 5.23e-26 | 158 |
| GO:004225426 | Esophagus | HGIN | ribosome biogenesis | 101/2587 | 299/18723 | 8.74e-19 | 4.03e-16 | 101 |
| GO:004227326 | Esophagus | HGIN | ribosomal large subunit biogenesis | 34/2587 | 72/18723 | 8.82e-12 | 1.06e-09 | 34 |
| GO:001607219 | Esophagus | HGIN | rRNA metabolic process | 72/2587 | 236/18723 | 2.26e-11 | 2.56e-09 | 72 |
| GO:000636419 | Esophagus | HGIN | rRNA processing | 69/2587 | 225/18723 | 4.53e-11 | 5.04e-09 | 69 |
| GO:003447010 | Esophagus | HGIN | ncRNA processing | 97/2587 | 395/18723 | 5.92e-09 | 3.90e-07 | 97 |
| GO:00346606 | Esophagus | HGIN | ncRNA metabolic process | 104/2587 | 485/18723 | 2.26e-06 | 8.23e-05 | 104 |
| GO:000170118 | Esophagus | HGIN | in utero embryonic development | 77/2587 | 367/18723 | 9.56e-05 | 2.05e-03 | 77 |
| GO:00018244 | Esophagus | HGIN | blastocyst development | 28/2587 | 106/18723 | 4.30e-04 | 6.47e-03 | 28 |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
| GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
| GO:0042273111 | Esophagus | ESCC | ribosomal large subunit biogenesis | 65/8552 | 72/18723 | 1.53e-15 | 9.82e-14 | 65 |
| GO:000182412 | Esophagus | ESCC | blastocyst development | 73/8552 | 106/18723 | 1.13e-06 | 1.40e-05 | 73 |
| GO:00018253 | Esophagus | ESCC | blastocyst formation | 29/8552 | 38/18723 | 1.18e-04 | 8.13e-04 | 29 |
| GO:002261312 | Liver | Cirrhotic | ribonucleoprotein complex biogenesis | 231/4634 | 463/18723 | 3.28e-32 | 6.86e-29 | 231 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WDR74 | SNV | Missense_Mutation | c.664G>C | p.Glu222Gln | p.E222Q | Q6RFH5 | protein_coding | tolerated(0.08) | possibly_damaging(0.649) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| WDR74 | insertion | Nonsense_Mutation | novel | c.372_373insAGAGAAGAGGCATACATCTAAGATGAGAAAGTTTCTGGGAGTGGAT | p.Leu125ArgfsTer7 | p.L125Rfs*7 | Q6RFH5 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| WDR74 | SNV | Missense_Mutation | rs766243027 | c.140N>T | p.Ala47Val | p.A47V | Q6RFH5 | protein_coding | tolerated(0.13) | benign(0.006) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| WDR74 | insertion | Frame_Shift_Ins | novel | c.741_742insT | p.His248SerfsTer8 | p.H248Sfs*8 | Q6RFH5 | protein_coding | TCGA-C5-A905-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| WDR74 | SNV | Missense_Mutation | c.351G>T | p.Lys117Asn | p.K117N | Q6RFH5 | protein_coding | tolerated(0.3) | probably_damaging(0.987) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| WDR74 | SNV | Missense_Mutation | c.712N>A | p.Gly238Arg | p.G238R | Q6RFH5 | protein_coding | tolerated(0.35) | benign(0.031) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| WDR74 | SNV | Missense_Mutation | c.878T>G | p.Leu293Trp | p.L293W | Q6RFH5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| WDR74 | SNV | Missense_Mutation | c.991G>C | p.Glu331Gln | p.E331Q | Q6RFH5 | protein_coding | tolerated(0.1) | benign(0.009) | TCGA-DC-4745-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD | |
| WDR74 | SNV | Missense_Mutation | c.915N>T | p.Glu305Asp | p.E305D | Q6RFH5 | protein_coding | tolerated(0.36) | possibly_damaging(0.451) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| WDR74 | SNV | Missense_Mutation | rs200001030 | c.650N>A | p.Arg217His | p.R217H | Q6RFH5 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |